Posted by Michael Wonder on 15 Jan 2019
Valeo Pharma and Zambon announce the approval of Onstryv (safinamide) for Canada
15 January 2019 - New treatment option for estimated 100,000 Canadians living with Parkinson's disease.
Zambon and Valeo Pharma today announce the approval of Onstryv (safinamide) for the treatment of Parkinson's disease in Canada.
Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality, sales and marketing, and distribution activities in Canada.
